NEW YORK – Immuneering on Thursday said it signed a clinical supply agreement with Regeneron to obtain the anti-PD-1 therapy Libtayo (cemiplimab) for a Phase IIa trial testing Immuneering's MEK ...

Vast's bold ambition: developing Haven-1, the first commercial space station. Learn about their successful primary structure qualification proof test.

Vast has started testing a qualification model of its first commercial space station but has pushed back the launch of that ...

Community empowerment is meant to uplift local groups and individuals by creating a sense of shared ownership of their ...

The exercise scientist recently shared a video with his tops tips for maximizing chest gains—especially for those who have ...

Age and UAR had good predictive value for 1-, 3-, and 5-year all-cause death in diabetic patients, and the combination of UAR and age had the highest predictive value. An easy and intuitive prognostic ...

We're nearing the end of Phase 5 of the MCU which marks the midway point of The Multiverse Saga, following the releases of Agatha All Along and Deadpool & Wolverine in 2024. This year sees the ...

The upcoming Phase 1/2 clinical trial, dubbed RESET-MS, will enroll adults, ages 18-60, who have either relapsing or progressive forms of MS. To be eligible, patients with relapsing MS must have ...

At seven-years follow up, invasive disease-free survival was 80.8% with adjuvant T-DM1 and 67.1% with adjuvant trastuzumab alone. Overall survival was 89.1% with T-DM1 and 84.4% with trastuzumab ...

The initial phase will last six weeks, and will involve a limited prisoner exchange, the partial withdrawal of Israeli troops in Gaza and a surge of aid into the enclave. Thirty-three Israeli ...

Israel believes the bodies of dead hostages will also likely be among 33 people released during the first phase of the deal. Quoting q diplomat close to the negotiations, CNN reported that a final ...

NEW YORK--(BUSINESS WIRE)--Signet Therapeutics (“Signet”), a clinical-stage biotech company leveraging organoids and AI to develop first-in-class cancer therapies, today announced that the first ...